Y-Intercept (HK)’s Lifecore Biomedical LFCR Stock Holding History

Y-Intercept (HK)’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-24,552	Closed	-$130K	–	1671
2024 Q1	$130K	Buy	24,552 +10,867	+79%	+$77.7K	0.01%	1239
2023 Q4	$84.7K	Buy	+13,685	New	+$95K	0.01%	1120
2023 Q3	–	Sell	-26,258	Closed	-$254K	–	1356
2023 Q2	$254K	Buy	+26,258	New	+$160K	0.03%	839

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VWA

Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return

Y-Intercept (HK)'s LFCR Position: Q2 2024 in Review

Y-Intercept (HK) sold out of Lifecore Biomedical (LFCR) in Q2 2024, closing a stake of 24,552 shares — an estimated $130K sold.

Y-Intercept (HK) first reported a position in LFCR in Q2 2023 and held it in 3 quarters. The position peaked at $254K in Q2 2023. 75 funds tracked by Wall St. Rank hold LFCR as of Q2 2024.

Y-Intercept (HK) reported no remaining Lifecore Biomedical position as of Q2 2024 after selling out during the quarter.
Y-Intercept (HK) sold 24,552 Lifecore Biomedical shares in Q2 2024, an estimated $130K.
Y-Intercept (HK) first reported a position in Lifecore Biomedical in Q2 2023 and held it in 3 quarters.
Y-Intercept (HK)'s Lifecore Biomedical position peaked at $254K in Q2 2023.
75 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2024.

Based on Y-Intercept (HK)'s 13F filing for Q2 2024, filed 14 Aug 2024.